Deal Details

Natera Completes $460 Million Follow-On Offering

Healthcare

Natera follow-on offering

Summary

Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) recently completed an upsized follow-on offering of 13,144,500 shares of its common stock at a price to the public of $35.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,714,500 shares of common stock, generating gross proceeds of approximately $460.1 million. Natera intends to use the net proceeds from this offering for continued investments in research and development for the Company’s core technologies as well as general corporate purposes.

Baird served as a lead manager on this offering.

About

Natera is a global leader in cell-free DNA testing, dedicated to oncology, women’s health and organ health. The Company aims to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrated high accuracy. Natera, Inc. is headquartered in Austin, Texas.

Healthcare

Natera follow-on offering